There are vastly more possible drug-like molecules than any chemist could ever screen. Here is how generative models are actually being used to search that space, and where the approach still runs into hard limits.
No single rulebook governs artificial intelligence in drug development. Instead, three different regulators are moving at three different speeds, and knowing exactly where each one stands is now part of the job.
FDA's paper trail on artificial intelligence is longer and more scattered across centers than most bench scientists realize. Here is what each document actually says, and which ones apply to drugs rather than devices.
Patent law was not written with generative models in mind. As AI becomes central to drug discovery, questions about ownership, inventorship, and data sharing are being answered in real time, not always consistently.
A model that says a molecule scores 0.87 has not told a chemist anything actionable. Explainability is what turns a score into a design decision, and it is harder to get right than it sounds.
Antibody drug discovery poses a different set of AI problems than small molecules. Here is what is actually working for biologics, and how far it is from designing an antibody from scratch.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.